PUBLICACIONES

ABVAC40

AB1601 phase 2 study of ABvac40, an anti-Aβ40 vaccine: safety and immunogenicity of a cross-over extension

Poster presentation AAIC 2023. María Pascual-Lucas, et al.

+Info

ABvac40 elicits a predominantly Th2 immune response that supports its excellent safety profile

Poster presentation CTAD 2022—ABVac40 Safety profile information Montañes M, Martín C, Castillo S et al.

+Info

UPDATE PHASE 2 STUDY OF ABVAC40, AN ACTIVE VACCINE ANTI-AΒ40 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR VERY-MILD ALZHEIMER’S DISEASE

Poster Presentation ADPD 2022 – TOP LINE DATA (Part A) Phase 2 ABvac40 Molina E, Castillo S, Lacosta AM et al.

+Info

Safety, tolerability and immunogenicity of an active anti-Abeta40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial

Lacosta AM, Pascual-Lucas M, Pesini P, et al. Alzheimers Res Ther. 2018; 10:12.

+Info

ABtest-ms

Clinical utility of an antibody-free LC-MSmethod to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study

Jose Antonio Allué, et al. Alzheimer’s Dementia Diagnosis Assessment Disease Monitoring 2023

+Info

Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity

Chun Ming Young, et al. Frontiers in Anging Neuroscience 2023.

+Info

Association of plasma Aβ42/Aβ40 with episodic memory performance and brain atrophy in individuals at risk of Alzheimer’s disease

Poster presentation ADPD 2023. María Pascual-Lucas, et al.

+Info

Clinical performance of an antibody‑free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline

Pascual-Lucas M, Allué JA, Sarasa L et al. Alzheimer’s Research & Therapy 2023; 15:2

+Info

Comparative performance of plasma Aβ42/Aβ40 and p‐tau181 for the detection of early brain amyloid deposition in individuals with subjective cognitive decline.

Poster presentation CTAD 2022—ABtest MS FACEHBI Cohort Pascual-Lucas M, Allué JA, Sarasa L et al.

+Info

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Janelidze S, Palmqvist S, Leuzy A et al. Alzheimer’s Dement 2022; 18:283-293

+Info

Plasma Aβ42/Aβ40, measured by a novel mass spectrometric method, identifies early amyloid deposition in individuals at risk of Alzheimer’s disease (FACEHBI Cohort)

Oral Presentation ADPD 2022 – AbtestMS_FACEHBI Allué JA, Sarasa L, Pascual-Lucas M

+Info

ACCURATE DISCRIMINATION OF BRAIN AMYLOID STATUS IN THE MULTI-CENTRIC A4 STUDY BY PLASMA Aβ42/Aβ40 MEASURED WITH A NOVEL HPLC-MS/MS METHOD

Poster Presentation ADPD 2022 – AbtestMS_A4 Study Sarasa L, Pascual-Lucas M, Allué JA et al.

+Info

The global Alzheimer’s Association round robin study on plasma amyloid β methods

Pannee J, Shaw LM, Korecka M at al. Alzheimers Dement 2021; 14;13(1):e12242

+Info

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations

Cullen N, Leuzy A, Palmqvist S et al. Nature Aging 2021; 1:114–123

+Info

Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort

Jang H, Kim Js, Lee HJ et al. Alz Res Therapy 2021; 13:179

+Info

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Janelidze S, Teunissen CE, Zetterberg H et al. JAMA Neurol. 2021;78:1375-1382.

+Info

ABtest-ia

ABtest-IA: A NEW RELIABLE TOOL FOR THE QUANTIFICATION OF Aβ40 AND Aβ42 IN CSF

Poster presentation AAIC 2022—ABtest IA CSF Validation Fandos N, Romero J, Pascual-Lucas M et al.

+Info

Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease–related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.

Verberk IMW, Misdorp E, Koelewijn J et al. Alzheimers Dement 2022; 18:1484-1497.

+Info

The global Alzheimer’s Association round robin study on plasma amyloid β methods

Pannee J, Shaw LM, Korecka M at al. Alzheimers Dement 2021; 14;13(1):e12242

+Info

Longitudinal evaluation of the natural history of amyloid-β in plasma and brain

Burnham SC, Fandos N, Fowler C, et al. Brain Communications. 2020; 2, 1-7.

+Info

Total Abeta42/Abeta40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis

Doecke JD, Pérez-Grijalba V, Fandos N, et al. Neurology. 2020; 94: e1580-e1591.

+Info

Plasma Abeta42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study

Pérez-Grijalba V, Romero J, Pesini P, et al. J Prev Alzheimers Dis. 2019-b; 6:34-41.

+Info

Plasma Abeta42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

Pérez-Grijalba V, Arbizu J, Romero J, et al. Alzheimers Res Ther. 2019; 11:96.

+Info

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

Risacher SL, Fandos N, Romero J, et al. Alzheimers Dement (Amst). 2019; 11:510-519.

+Info

Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

De Rojas I, Romero J, Rodríguez-Gómez O, et al. Alzheimers Res Ther. 2018; 10:119.

+Info

Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals.

Fandos N, Pérez-Grijalba V, Pesini P, et al. Alzheimers Dement (Amst). 2017; 8:179-187.

+Info

Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Abeta40 and Abeta42 Peptides in Plasma.

Pérez-Grijalba V, Fandos N, Canudas J, et al. J Alzheimers Dis. 2016; 54:751-62.

+Info